These results suggest that potential therapies capable of targeting TRAF6‐mediated K63 ubiquitination in Tregs may be highly effective at breaking tolerance and bolstering the anti‐tumor immunity by undermining Treg function. This evidence concerns the gene TRAF6 and neoplasm.